Nuvation Bio (NUVB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
Annual Meeting scheduled for May 21, 2026, via live webcast, with record date of March 25, 2026.
Stockholders will vote on director elections, ratification of KPMG LLP as auditor, and an advisory say-on-pay vote.
Voting instructions provided for online, phone, and mail participation; quorum requirements detailed.
Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Three proposals: election of three directors, ratification of KPMG LLP as auditor for 2026, and advisory approval of executive compensation.
Class A and Class B stockholders vote together for two directors; Class B stockholders vote separately for one director.
Stockholder proposals for the 2027 meeting must be submitted by December 11, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
Board consists of seven members, divided into three classes with staggered three-year terms.
Majority of directors are independent per NYSE standards; Dr. Hung serves as Board Chair, Mr. Bazemore as Lead Independent Director.
Board committees: audit, compensation, and nominating/corporate governance, each with defined charters and responsibilities.
Board and committees met regularly in 2025, with all directors attending at least 75% of meetings.
Latest events from Nuvation Bio
- Ibtrozi's first-line growth, global deals, and profitability highlight strong Q1 momentum.NUVB
Q1 20264 May 2026 - IBTROZI drives strong growth in ROS1+ NSCLC as safusidenib and DDCs advance in oncology.NUVB
Investor presentation4 May 2026 - First-line patient growth and robust pipeline drive strong outlook and international expansion.NUVB
TD Cowen 46th Annual Health Care Conference29 Apr 2026 - IBTROZI sets a new standard in ROS1+ NSCLC with high efficacy, safety, and rapid adoption.NUVB
Corporate presentation22 Apr 2026 - Director compensation figures for 2025 were corrected, clarifying cash and option awards.NUVB
Proxy filing21 Apr 2026 - IBTROZI leads in ROS1 lung cancer with rapid uptake, superior efficacy, and expanding indications.NUVB
The Citizens Life Sciences Conference 202611 Mar 2026 - IBTROZI's clinical success and global deals drive growth, with safusidenib advancing in pivotal trials.NUVB
Corporate presentation3 Mar 2026 - Rapid IBTROZI uptake, Eisai partnership, and safusidenib trials drive long-term growth.NUVB
Q4 20253 Mar 2026 - FDA approval and rapid IBTROZI launch drove strong Q2 revenue and robust cash reserves.NUVB
Q2 20253 Feb 2026